HC Wainwright reaffirmed their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA - Free Report) in a research note released on Friday,Benzinga reports. HC Wainwright currently has a $45.00 price objective on the stock.
ORKA has been the subject of a number of other research reports. Wolfe Research assumed coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 target price for the company. Wedbush reissued an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Finally, Stifel Nicolaus began coverage on shares of Oruka Therapeutics in a report on Friday, October 11th. They set a "buy" rating and a $49.00 price target for the company. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Oruka Therapeutics has a consensus rating of "Buy" and a consensus price target of $39.86.
Read Our Latest Stock Report on ORKA
Oruka Therapeutics Price Performance
Shares of ORKA traded up $0.23 during midday trading on Friday, hitting $11.14. The company's stock had a trading volume of 78,689 shares, compared to its average volume of 311,148. Oruka Therapeutics has a one year low of $10.61 and a one year high of $53.88. The company has a market cap of $389.94 million, a PE ratio of -1.79 and a beta of 0.77. The company's fifty day moving average price is $17.33.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $303,000. AlphaCentric Advisors LLC bought a new stake in Oruka Therapeutics in the fourth quarter valued at approximately $119,000. China Universal Asset Management Co. Ltd. acquired a new stake in Oruka Therapeutics during the 4th quarter valued at approximately $144,000. Franklin Resources Inc. bought a new position in Oruka Therapeutics during the 3rd quarter worth approximately $17,661,000. Finally, Geode Capital Management LLC acquired a new position in shares of Oruka Therapeutics in the 3rd quarter worth approximately $343,000. 56.44% of the stock is owned by institutional investors.
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Featured Articles
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
